Objectives: To review the issues that have arisen with the advent of translational research in terms of integration of data and knowledge, and survey current efforts to address these issues. Methods: Using examples form the biomedical literature, we identified new trends in biomedical research and their impact on bioinformatics. We analyzed the requirements for effective knowledge repositories and studied issues in the integration of biomedical knowledge. Results: New diagnostic and therapeutic approaches based on gene expression patterns have brought about new issues in the statistical analysis of data, and new workflows are needed are needed to support translational research. Interoperable data repositories based on standard annotations, infrastructures and services are needed to support the pooling and meta-analysis of data, as well as their comparison to earlier experiments. High-quality, integrated ontologies and knowledge bases serve as a source of prior knowledge used in combination with traditional data mining techniques and contribute to the development of more effective data analysis strategies. Conclusion: As biomedical research evolves from traditional clinical and biological investigations towards omics sciences and translational research, specific needs have emerged, including integrating data collected in research studies with patient clinical data, linking omics knowledge with medical knowledge, modeling the molecular basis of diseases, and developing tools that support in-depth analysis of research data. As such, translational research illustrates the need to bridge the gap between bioinformatics and medical informatics, and opens new avenues for biomedical informatics research.
Access to information, analysis of data, and integration of knowledge are key components of biomedical research. Scientists and physicians must be able to integrate their data with other data, to combine information from multiple sources, and to compare their results to prior knowledge. This paper illustrates the role of knowledge in biomedical research, with focus on omics disci plines, and surveys current efforts to address the needs of biomedical re searchers for better access to informa tion and better integration of data and knowledge.
Trends in Biomedical Research and their Impact on Bioinformatics
The current era of biomedical research can be characterized by what NIH Di rector E.A. Zerhouni calls the "four Ps" of medicine: Predictive, Personalized, Preemptive and Participatory 1 . Risk fac tors of diseases must be identified early in order to adapt counter-measures, es pecially for long-term, chronic diseases. Treatments must be tailored in order to take into account the characteristics of individual patients. Shifting the fo cus of medicine from the current doc tor-centric, curative paradigm to pre venting diseases will require the active involvement of patients. With the ad vent of personalized medicine, bio markers, including genetic markers, will be tested for each patient in order to diagnose specif ic forms of diseases, predict disease progression and patient outcome, and propose the best thera peutic options. This scenario puts genomics and pharmacogenomics at the centre of medicine [1] . This new vi sion of personalized medicine is sup ported by very active biomedical re search. As the role of "omics" disciplines 2 in biomedical research be comes more important, classical clini cal studies must be adapted to these new approaches. New models of diseases have emerged from these studies. The genes identified through omics studies provide clues to possible pathogenetic mechanisms and are likely to be useful in developing diagnostic tests and adapting therapeutic responses. Discov eries typically begin at "the bench" with basic research. Then they must be trans lated into practical applications and progress to the clinical level, the patient's "bedside." In parallel, clinical researchers make novel observations about the nature and progression of dis ease that often stimulate basic investi gations. This exchange of information 2 omics is a generic term for new disciplines enabled by high-throuput technologies, such as genomics, 1 http://nihroadmap.nih.gov/ transcriptomics, and proteomics describes translational research or trans lational medicine: researchers and phy sicians applying newly gained knowl edge to the clinic -and back again to the bench 3 . Such recent changes in bio medical research have brought about new challenges for bioinformatics and medical informatics. The analysis of genomic studies and the new workflows between research and health care gen erate greater demand for accessing and integrating information.
New Diagnostic and Therapeutic Approaches
Disease classification based on gene expression patterns. Over the past de cade, biomedical research has evolved to mine gene expression profiles for clues to the pathogenesis, prognosis and treatment of human diseases. In oncol ogy, for example, this research rests on the premise that extraordinary insights into the molecular basis of cancer can be obtained by analyzing gene expres sion in patient-derived tumor samples, in addition to experimental models. DNA microarrays (DNA chips) are used to monitor the gene expression (i.e., a proxy for gene activity) of thou sands of genes simultaneously across the human genome. This technique involves the extraction of RNA from tumor samples and its subsequent fluorescent labeling and hybridization to an array of DNA probes. Microarrays covering nearly the entire human genome are now available. In a series of experi ments, Golub demonstrated that the classification of cancer --specifically two principal forms of acute leukemia --could be achieved by using DNA microarrays to monitor gene expres sion, without a prior molecular underhttp://nihroadmap.nih.gov/clinicalresearch/ overview-translational.asp standing of this distinction [2] . This finding implies that such methodolo gies can be applied to the molecular dissection of cancers. This approach has been used for the molecular clas sification of many tumor types, includ ing lymphoma (e.g., [3] ), prostate can cer (e.g., [4] ), brain tumors (e.g. [5] ), and lung cancer (e.g., [6] ). Similar approaches have demonstrated that pat terns of gene expression (or gene ex pression "signatures") may be found across different tumor types. For ex ample, Golub et al identified a signa ture of metastatic propensity across prostate, breast, and lung cancers, sug gesting that a genetic test performed at the time of diagnosis might predict the future behavior of some tumors [7] . While most studies of gene expression have been carried out on tissue samples, some have used peripheral blood samples (e.g. [8] ), thus extending the applicability of this technique. Pharmacogenomics. Gene expressionbased approaches are also widely used in pharmacology (e.g., [9] ). The ex pectation here is that genomic ap proaches might lead to the discovery of molecules and compounds capable of modulating biological processes in cells. Drug discovery typically starts with prior knowledge of a target gene that is biologically relevant to a dis ease state (e.g., a gene mutation in can cer). The protein product of this gene is then biochemically purified, and a collection of compounds screened in vitro for their ability to bind to the pro tein. Novel approaches to drug discov ery are based on genomics. Gene expression-based methods are used to identify candidate drugs that modulate previously intractable targets. These genes and gene products can serve as potential therapeutic targets or tools in addition to providing diagnostic and prognostic markers, as well as end points for clinical trials. In cancer re search, this approach has been applied to the discovery of substances that may induce the maturation of abnormal cells (e.g., acute myeloid leukemia cells), in hibit androgen or estrogen action in can cer cells, inhibit angiogenesis associ ated with tumor cell proliferation or inhibit the activity of the causal pro tein in some tumors (e.g., Ewing sar coma [10] ).
The functional consequences of ge netic polymorphisms have been exam ined for several drug-metabolizing en zymes [11] . Variants leading to reduced or increased enzymatic activity com pared to the wild-type alleles have been identified. The possible application of genotyping has been discussed for sev eral pathologic conditions. Among many other examples, the acetylator status has long been used for predict ing isoniazid-induced hepatic toxicity in tuberculosis [12] , and associations between genetic variability and re sponse to beta-adrenergic medications have been explored [13] . The associa tion between gene expression and re sponse to treatment holds the promise of personalized medicine, as doctors will be able to individualize drug therapy and provide specific therapies to those most likely to respond, while avoiding therapies in those most likely to suffer adverse effects.
New Issues Related to the Analysis of Genomic Studies
Clinical trials provide an evaluation framework for interventions. Param eters are measured in patients under different types of interventions and the values of these parameters are compared across groups of subjects in order to identify associations between interven tions and outcomes. Traditional clini cal trials generally involve many sub jects in which only few parameters are measured. Conversely, omics studies typically generate a large number of measurements on the limited number of test subjects (relatively to the num ber of parameters measured). This im balance has created new issues involv ing statistics and bias [14] . Omics studies offer a potentially powerful approach to identifying new biomarkers, but many of them are plagued by a lack of consistency and reproducibility (e.g., [15] ). In principle, the inconsistency may be due to false positive studies, false negative studies or true variabil ity among heterogeneous groups. In order to avoid biases and get more re liable results, the data from individual experiments at different centers could be pooled and public data repositories used for comparative data analysis [16] . Moreover, the goal of omics approaches is also to acquire comprehensive, inte grated understanding of biology by studying all biological processes in ad dition to analyzing parameters individu ally (e.g., [17] ). Therefore, solutions exploiting prior knowledge about gene functions (e.g., in gene annotations databases) and multi-scale biological models have been proposed and are dis cussed in section 3.3.
New Workflows in Biomedical Research
In the context of translational research and translational medicine, information sharing between medical research, epi demiology and clinical medicine has been identif ied as a strong require ment. Translational research creates a bidirectional information transfer that accelerates trials and evaluates their clinical potential. In this framework, clinical data and biomarkers must be collected early in order to extract new knowledge and form new hypotheses from the mass of collected data. There fore the relationship between research, population studies and health care rests on the integration of the data and knowledge from these three areas: re search (scientific publications, public databases, experimental results), epide miology (e.g., cohort studies), and healthcare (clinical data stored in pa tient records).
Two main challenges have to be over come when automatically interrelating data from these different areas. First, these data are annotated to different terminologies and data referring to the same entity may be represented by dif ferent identifiers [18] . For instance, the disease "acute myeloid leukemia" is coded D015470 in bibliographic data bases indexed with MeSH, 91861009 in clinical records coded with SNOMED Clinical Terms® (SNOMED CT ® ) 4 , and C3171 in re search records annotated to the NCI Thesaurus 5 [19] . The second issue is that the data to be integrated are comple mentary in nature but intrinsically dif ferent (omics -pathology -anatomy physiology). Ontologies have been proven useful for data integration (e.g., [20, 21] ). Several ontologies have been developed in bioinformatics and in the biomedical domain. However, they are still incomplete (neither all concepts nor relations are present) and fragmented (ontologies are orthogonal and few bridges are established between complementary ontologies) (e.g., [22] ). Enrichment and integration of biomedi cal ontologies are therefore important stakes for translational medicine and bioinformatics, as well as for the fu ture links between these two disciplines (e.g., [23, 24, 25] 
Effective Data Repositories
Pooling experimental data requires the standard annotation of the experiments. It also requires interoperability among data repositories supported by standard services and workflows. Interoperable data repositories constitute an enabling resource for meta-analysis.
Repositories of Experimental Data
Public datasets have been created in re sponse to the growing demand for pub licly available repositories for highthroughput gene expression data. Such public repositories represent an impor tant resource for the biological research community as they provide unre stricted access to microarray data pub lished by other researchers. As such, they complement local in-house gene expression databases by providing ref erence data for comparative studies. Among them, the Gene Expression Omnibus (GEO) repository developed by the National Center for Biotechnol ogy Information (NCBI) is publicly accessible on the NCBI website at http:/ /www.ncbi.nlm.nih.gov/geo [26] . GEO archives and helps disseminate microarray and other forms of highthroughput data generated by the sci entific community [27] . GEO data can be viewed from the perspective of the experiment or the gene. The experi ment-centric view presents the entire study, while the gene-centric view dis plays quantitative gene expression mea surements for one given gene across a dataset, with links to gene annotations. Other efforts to archive experiments and make them accessible to the whole com munity include the Stanford Microarray Database (SMD) [28] (http://smd. stanford.edu) and the ArrayExpress database of microarray [29] (http:// www.ebi.ac.uk/arrayexpress), devel oped by the European Bioinformatics Institute. All these repositories promote standard exchange formats such as MAGE-TAB [30] . Moreover, data sub mitted to these repositories are required to have a common set of core elements. As many other resources in this do main, including local experimental da tabases, data sets in public reposito ries are compliant with the standards that def ine a minimum information about a microarray experiment. Broad adhesion to these standards facilitates the publication and retrieval of data, as it ensures consistency across datasets.
In addition to such wide-scale projects, more focused initiatives seek to collect all published data on a given medical topic. Specific pipelines and services have been developed in con junction with such focused databases. For example, the Oncomine initiative seeks to collect all published cancer microarray data (http://www. oncomine.org). To date, this effort has accumulated 18,000 cancer gene ex pression experiments. Automated analy ses can be performed to identify the genes, pathways, regulatory networks, and functional networks activated and repressed in human cancer. As described in [31] , all cancer microarray data de posited in GEO and SMD are automati cally copied to Oncomine and then stan dardized.
Data repositories may be extended with clinical data. With focus on three types of tumors --breast carcinoma, bladder carcinoma and uveal mela noma --the Integrated Tumor Transcriptome Array and Clinical data Analysis (ITTACA) centralizes public datasets containing both gene expres sion and clinical data on these tumors [32] . This system enables users to carry out different class comparison analy ses, including the comparison of ex pression distribution profiles, tests for differential expression and patient sur vival analyses and to compare personal results with the results in the existing literature (http://bioinfo.curie.fr/ ittaca).
Standard Annotations
The generation of large amounts of data and the need to share and compare these data bring about challenges for both data management and data annotation and highlight the need for standards. The Microarray Gene Expression Data (MGED) society is an international or ganization created in 1999 for facili tating sharing of functional genomics and proteomics array data. MGED has def ined the Minimum Information About a Microarray Experiment (MIAME) that corresponds to the minimum information that must be re ported about a microarray experiment to enable its unambiguous interpreta tion and reproduction. This standard has been used for years worldwide. The Microarray Gene Expression Object Model (MAGE-OM) and resulting markup language (MAGE-ML) provide a mechanism for standardizing data rep resentation for data exchange purposes [33] . Moreover, a common terminol ogy, the MGED Ontology (MO) has been developed by the Ontology Work ing Group of the MGED society to complement these standards. The ob jective of MO is to provide common 'terms for annotating experiments in line with the MIAME guidelines, i.e., to provide the semantics to describe a microarray experiment according to the concepts specif ied in MIAME' [34] .
(http://mged.sourceforge.net/ontolo gies/index.php.)
Similar efforts in the field of func tional annotation have established stan dard vocabularies for the annotation of genes and gene products [35] . With the aim of contributing to the unification of biological information, the Gene On tology (GO) has been developed since 2000 [36, 37] and has been adopted by most model organism databases, such as the Gene Ontology Annotation (GOA) database [38] (http:// www.ebi.ac.uk/GOA).
Moreover, some research communi ties have decided to standardize their data models and data types to address interoperability issues. One of the re quirements for a federated information system is interoperability, i.e., the abil ity of one computer system to access and use the resources of another sys tem. In order to meet this need, the U.S. National Cancer Institute Center for Bioinformatics (NCICB) has created the cancer Common Ontologic Repre sentation Environment (caCORE) to address interoperability issues in the field of cancer research [39] . The caCORE system includes controlled terminologies such as the NCI Thesau rus (NCIT) [40] , as well as common data elements (CDEs), which are named identifiers for the entities and attributes found in databases.
However, despite these standardiza tion efforts, not all the data created, stored, and made available in the bio medical domain are homogeneously represented. Because most biomedical systems have been developed indepen dently of each other, these systems do not have a common structure, nor do they share common data elements. Be cause determining the correspondences between heterogeneous data sources is complex and time-consuming, auto mated support is needed [41] . Several approaches have been proposed, either based on the comparison of data-ele ments (schema-level approaches) or based on the comparison of value sets of data elements coming from distinct sources (instance-level approaches) [42, 43, 44 ].
Infrastructures and Services
Biomedical research requires to pool and to integrate information from di verse data sources, which is facilitated by the use of common data models and common ontologies. Additionally, co ordinated research efforts typically span multiple institutions. Therefore, there is a need for an infrastructure that supports such collaborative efforts, with the objective of enabling more efficient access to the resources and sharing distributed computational re sources. To address this need, the U.S. National Cancer Institute (NCI) has initiated a nationwide effort, called the cancer Biomedical Informatics Grid (caBIG), to develop a federation of interoperable research information sys tems [45] . At the heart of the caBIG approach to federated interoperability is a Grid middleware infrastructure, called caGrid. [46] . Moreover, this in frastructure is based on the caCORE system mentioned earlier, which sup ports the creation of interoperable bio medical information systems. Similar efforts in Europe have established grid infrastructures for sharing computa tional resources in bioinformatics (e.g., http://www.embracegrid.info ) and en abling cooperative research in bio medical research [47] , for example in infectious diseases [48] and immune diseases [49] , as well as in cancer re search [50] .
More generally, grid technologies are expected to facilitate the launch and ongoing management of coordinated cancer research studies involving mul tiple institutions, to provide the abil ity to manage and securely share in formation and analytic resources. Additionally, grid computing supports high-throughput data analysis and pre dictive classification studies on large datasets [51] . Grid computing can also support the modeling of complex bio logical systems, which requires ad vanced computer simulations to bring together knowledge at all the different levels of biological understandingfrom the cell (e.g., gene function) to the organism (e.g., physiology) --in order to provide a coherent theory of biology, which can then be applied to clinical medicine.
In conjunction with the develop ment of distributed databases and grid computing, an increasing number of tools in biomedical informatics have been developed as Web Services, with potential applications in genomic medicine (e.g., [52] ). Web Services of fer two major benefits for the biomedi cal community: interoperability and re usability. Web Services use standard communication protocols over the Internet, which makes them virtually platform-independent. Instead of de veloping a specific service locally, de velopers can reuse Web Service com ponents in their own applications. With the objective of implementing complex data analysis processes, Web Services must be associated with workflow man agement systems (e.g., [53] ). Environ ments such as Taverna provide a lan guage and software tools to create and execute workflows and to construct highly complex analyses over public and private data and computational re sources [54, 55] .
In the near future, these efforts will hopefully be strengthened by the cre ation of publicly available registries that describe all these services in a stan dard manner. For example, Stevens et al [56] recommend the use of ontolo gies to express the semantic informa tion associated with the description of Web Services. The design of broadcoverage formal models of tasks and their representation as formal ontolo gies will facilitate the discovery of ser vices, their selection and their compo sition into dynamic workflows [57] .
Meta-analysis
One advantage of integrating large num bers of microarray studies and compil ing them in a data-warehouse is that it makes it possible to compare the re sults of different studies and to deter mine which methods are robust and pro duce consistent results across a range of studies. There are, however, many problems associated with the compari son of gene expression profiles across disparate microarray data sets. In stud ies performed in 2004 and 2007 by sev eral teams, the authors demonstrated that the consistency of replicates in each experiment exhibits a large degree of variation. Different technologies seemed to show good agreement within and across labs using the same RNA samples. The variability between two labs using the same technology was higher than that between two technolo gies within the same lab. Moreover, the source of RNA samples can make a dif ference in microarray data [58, 59, 60] .
Several methods have been developed to address these variability issues in mul tiple, independent data sets generated on various platforms. Among others :
• Comparative meta-profiling is used in Oncomine to compare differen tial expression measured in each data set [61] . In this approach, users first select appropriate studies for comparison, and then use meta analysis to identify the genes that are significantly overexpressed or underexpressed across multiple in dependent studies.
• SubMap is an unsupervised sub class mapping method, which reveals common subtypes between independent data sets. This method revealed the correspondence between several cancer-related data sets. Notably, it identified common subtypes of breast cancer associated with estrogen receptor status, and a subgroup of lymphoma patients who share similar survival patterns, thus improving the accuracy of a clinical outcome predictor [62] . The approach associating data integra tion and meta-analysis helps address sta tistical methodological issues [63] . Data related to the same pathologic condi tion from different laboratories may be analyzed (e.g. [64] ). For example, Bhanot et al have used classification models with non-Hodgkin's lymphomarelated microarray data from different laboratories [65] , and Lyman et al have used meta-analysis techniques to detect predictors of recurrence-free survival in breast cancer [66] . Data integration may also be used with data correspond ing to different diseases, for example different types of cancers [67] . Differ ent kinds of experimental data can be integrated (e.g., microarray and prote omics). Moreover, data from different species can be integrated. For example, English and Butte evaluated 49 obesityrelated genome-wide experiments in cluding microarray, genetics, proteomics and gene knock-down from human, mouse, rat and worm. They created an integrative model and showed that in tersecting the results of experiments sig nificantly improved the sensitivity, specificity and precision of the predic tion of obesity-associated genes [68] .
Integrating Knowledge
Computable forms of knowledge in clude knowledge bases and ontologies. Existing resources are often incomplete and need to be enriched and integrated. Incorporating prior knowledge into the analysis of gene expression datasets has been shown to improve the results.
Knowledge sources and ontologies
Multiple knowledge bases. The number of data sources has grown tremendously over the last decade. Frey et al mention that around 900 biological public data bases (e.g., genomic, proteomic, metabolomic, and others) were avail able in 2007, representing a vast amount of information about genes, proteins, diseases and their interrelations [1] . Besides repositories of experimental data, many knowledge resources are also publicly available. Such resources typically compile manually curated knowledge extracted from the biomedi cal literature and other sources. [69] . Some ontologies are levelspecific such as GO at the cellular level, or SNOMED at the organism level. Ontologies can be overlapping in part. For example, subcellular anatomical entities are defined in both the FMA and the Cell Component axis of GO [70] . In contrast, some ontologies may reuse the entities defined in other on tologies. For example, reasoning over the anatomical location of diseases in a clinical ontology can be delegated to the anatomical ontology in which the anatomical entities are defined [71] . Ontology repositories. The use of on tologies is a key element to inter operability among resources. For this reason, high-quality ontologies must be available to the community, ideally at no cost and without any constraints Fig. 1 Interrelations among biomedical ontologies impeding their use or redistribution. The Open Biomedical Ontologies (OBO) are a collection of controlled vocabularies freely available to the bio medical community. Web-based ontol ogy portals such as the BioPortal (http:/ /www.bioontology.org/tools/portal/ bioportal.html) allow users to browse, search, and visualize ontologies (and metadata) in the library, and to submit an ontology to the library. Ontology portals also tend to include features popularized by the "Web 2.0" move ment, including the collaborative re view of ontologies by users [72] . The need for innovative technology and methods that allow scientists to record, manage, and disseminate biomedical information and knowledge in machine processable form gave rise, in part, to initiatives such as the National Center for Biomedical Ontology (NCBO) cre ated in 2005 6 [73] . Ontology federation. The development of OBO ontologies is regulated within the OBO Foundry, which defines a set of shared principles governing ontol ogy development [74] . Knowledge in tegration will also benefit from the de velopment of top-domain ontologies, such as BioTop [75] . Such ontologies define the top-level classes of biomedi cal ontologies and can be used for link ing f iner-grained domain ontologies. Of note, some recently created ontolo gies were designed to be interoperable and to incorporate accurate representa tions of biological reality [74] . For ex ample, the PRotein Ontology (PRO) includes connections to other ontolo gies, including GO. It is expected that the connection of protein forms to GO classes using appropriate relations will support accurate functional annotation. Analogously, relations defined between protein classes and the OBO Disease Ontology will facilitate disease under standing [76] . Until the development of federated biomedical ontologies is fully orchestrated by organizations such as the OBO Foundry -if it ever is, there will be a need for creating ad hoc bridges across existing ontologies, which is one of the objectives of the Unified Medical Language System (UMLS) 7 developed by the US National Library of Medi cine. The UMLS Metathesaurus inte grates 1.4 million concepts from over one hundred terminologies in use in life sciences, as well as some 12 million relations among these concepts. UMLS concepts are not only inter-related, but may also be linked to external resources such as GenBank, providing easy access to the knowledge contained in these re sources [77] . More generally, various ap proaches to aligning existing ontologies are discussed in [78] . Semantic Web for Health Care and Life Sciences. Knowledge integration efforts have benef ited from the development of Semantic Web technologies [21] . In the past few years, the World-Wide Web Consortium (W3C) has developed a set of standards and tools to support the vision of a flexible, integrated, auto matic and self-adapting Web. Some of these technologies are now mature and have started making an impact in the life sciences. Semantic Web languages include the Resource Description Framework (RDF), a variety of data interchange formats (e.g., RDF/XML, N3, Turtle, N-Triples) and notations, such as RDF Schema (RDFS), and the Web Ontology Language (OWL), all of which are intended to provide a for mal description of concepts, terms, and relationships within a given knowledge domain. OWL provides formal compu tational definitions, as well as tools for reasoning, in order to facilitate ontol ogy development and ontology main tenance. Therefore most health science ontologies, including those originally developed in OBO format [79] , have been converted to OWL [80, 81] .
Knowledge Enrichment
Standard terminologies, such as the Gene Ontology, are widely used in da tabases and knowledge bases as con trolled vocabularies for functional an notations and largely facilitate comparative functional analysis. How ever, the functional annotation of gene products is not always consistent across databases and often remains incomplete. Although GO curators adhere to the same protocols and standards while as signing GO annotations, specific anno tation procedures and the specialization of curators vary across groups. Meth ods have been developed to assess the consistency of GO annotation across model organism databases (e.g., [82] ). Enriching biological knowledge bases. Determining the function of uncharac terized proteins remains a major chal lenge and is an active field of research. Various knowledge sources have been explored, including large scale proteinprotein interaction assays, global mRNA expression analyses and system atic protein localization studies in [83] ). Various techniques have been explored as well to generate functional annota tion predictions, among which informa tion theory-based semantic similarity, based on existing GO annotations [84] .
Methods based on natural language processing and statistical techniques have been widely used for years for mining free text and extracting GO an notations. While the content of most biological databases is acquired through careful manual curation of literature and data, the increasing volume of bio the increasing number of gene prod ucts in need of annotation are likely to overload the manual curation process.
Consequently, text mining techniques are often employed to retrieve and ex tract functional annotation from the lit erature. For example, GoPubMed uses GO to organize the results of a PubMed search [85] . The BioCreAtIvE initia tive, with tasks such as gene name nor malization and identification of func tional annotation from free text, demonstrated that term recognition techniques are suitable for real appli cations in biology [86] . However, au tomatic annotation techniques generally require additional knowledge process ing and had lesser performance than gene identification tasks. Daraselia et al also showed the usefulness of com bining NLP techniques (protein anno tation extracted from Medline) with additional knowledge (information from protein-protein interactions datasets) [87] . Enriching biomedical ontologies. Analogous to the methods devoted to quality assurance and enrichment of knowledge bases, methods have been developed for the evaluation of ontolo gies, including terminology enrichment and consistency checking.
Terminology enrichment techniques are used for identifying missing rela tions in terminologies. For example, GO lacks explicit associative relations across its three hierarchies, which may impede the consistent clustering of gene prod ucts according to functional character istics. For instance, while the gene APOC3 is associated with both the mo lecular function 'lipid transporter ac tivity' and the biological process 'lipid transport', APOH is only annotated with 'lipid transporter activity'. To address this issue, various approaches to sug gesting new relations among biologi cal terms have been proposed, based on lexical and statistical phenomena.
Biological terms are often found as proper substrings of other terms. Compositionality of terms has been used to suggest semantic relations among GO terms directly [88, 89] or through ChEBI terms [90] . Moreover, Mungall proposed a formal language, Obol, for def ining allowed composi tional patterns among terms from OBO ontologies [91] . Statistical and data mining techniques have also been ap plied to biological knowledge bases annotated to the GO in order to auto matically extract candidate relations among GO terms and help enrich on tologies with associative relations [92] .
When ontologies are represented with formal languages and defined in reference to formal upper-level ontolo gies, it becomes possible to validate ex isting relations among classes and to identify new relations. OWL, the Web Ontology Language, is often used to represent the concepts and the relations in ontologies. OWL is more expressive than XML, RDF, and RDF-S, because it contains additional features for de scribing properties and classes formally. Such features include equivalence and disjointness among classes, cardinality of relations (e.g., "exactly one"), char acteristics of properties (e.g., symme try), and enumerated classes. Using the formal semantics of the OWL language makes it possible to reason about these classes and their instances and to en sure the consistency of these ontologies.
Strategies for Analysis and Applications
Key to the analysis of omics data is the integration of prior knowledge. Of spe cial interest are methods that include functional characteristics from the be ginning of the data analysis process, integrate medical knowledge with bio logical knowledge, and combine min ing techniques with inference-based knowledge processing.
The analysis of transcriptomic data is classically carried out in two steps. First, data are clustered according to gene expression levels in order to cre ate three clusters: over-expressed, un der-expressed and invariant. Only sub sequently is functional information introduced in order to characterize the clusters "functionally". One of the limi tations of this approach is that func tional similarity does not contribute to the clustering process. Methods includ ing functional annotation from the be ginning of the analysis have been pro posed (e.g., [93] ). These methods rely, for example, on semantic similarity measures among genes based on func tional annotations [94] .
Moreover, besides gene expression, proteomic patterns, functional charac teristics of genes and the medical fea tures associated with a sample (e.g., phenotype, clinical history, environ mental factors, experimental condi tions) could contribute to the cluster ing process. Such characteristics can be represented as UMLS concepts [95] , NCIT or SNOMED CT concepts [96, 97] . Once annotated to these ontolo gies, the datasets can be clustered in such a way that the annotations themselves participate in the clustering, along with the expression prof iles of the genes. More generally, knowledge integration has been shown to increase the power of analysis in several genomic studies. Butte has developed an approach based on the UMLS [95] , while other authors have integrated Entrez Gene and GO [98] . Chabalier has proposed a method for integrating information from the KEGG pathway database and the GO annotation repository into a disease ontology [99] .
Various data mining techniques have been applied to biomedical data analy sis (e.g., [100] , [101] ). Among data mining techniques, association rule mining, used widely in the area of mar ket basket analysis, can be applied to the analysis of biological data as well. Based on the frequencies of co-occur rence between a gene G and a pheno type P, a typical rule would be: "if P is present, then G is present". Association rules can reveal biologically relevant associations between different genes or between environmental effects and gene expression profiles. The mining tech niques may include negative rule gen eration (e.g., [102] ) in addition to posi tive rule generation. Ideally, data mining techniques should be combined with inference-based knowledge pro cessing. For example, the classification capabilities associated with ontologies may be used to aggregate annotations in order to improve the support and confidence values of association rules. More generally, knowledge bases and inference may contribute to increase the power of data mining techniques.
Conclusion
As biomedical research evolves from traditional clinical and biological re search towards omics sciences and trans lational research, specific needs have emerged, including integrating data col lected in research studies with patient clinical data, linking omics knowledge with medical knowledge, modeling the molecular basis of diseases, and devel oping tools that support in-depth analy sis of research data. As such, transla tional research illustrates the need to bridge the gap between bioinformatics and medical informatics [103] , and opens new avenues for biomedical informatics research.
